TY - JOUR
T1 - Clinical and molecular correlates of the Index of Severity for Eosinophilic Esophagitis
AU - Sato, Hiroki
AU - Dellon, Evan S.
AU - Aceves, Seema S.
AU - Arva, Nicoleta C.
AU - Chehade, Mirna
AU - Collins, Margaret H.
AU - Davis, Carla M.
AU - Falk, Gary W.
AU - Furuta, Glenn T.
AU - Gonsalves, Nirmala P.
AU - Gupta, Sandeep K.
AU - Hirano, Ikuo
AU - Hiremath, Girish
AU - Katzka, David A.
AU - Khoury, Paneez
AU - Leung, John
AU - Menard-Katcher, Paul
AU - Pesek, Robbie
AU - Peterson, Kathryn A.
AU - Pletneva, Maria A.
AU - Spergel, Jonathan M.
AU - Wechsler, Joshua B.
AU - Yang, Guang Yu
AU - Rothenberg, Marc E.
AU - Shoda, Tetsuo
N1 - Publisher Copyright:
© 2024 American Academy of Allergy, Asthma & Immunology
PY - 2024/8
Y1 - 2024/8
N2 - Background: The Index of Severity for Eosinophilic Esophagitis (I-SEE) is a new expert-defined clinical tool that classifies disease severity of eosinophilic esophagitis (EoE). Objective: We aimed to determine whether I-SEE is associated with patient characteristics, molecular features of EoE, or both. Methods: We analyzed a prospective cohort of patients with EoE from the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). Associations between I-SEE and clinical and molecular features (assessed by an EoE diagnostic panel [EDP]) were assessed. Results: In 318 patients with chronic EoE (209 adults, 109 children), median total I-SEE score was 7.0, with a higher symptoms and complications score in children than adults (4.0 vs 1.0; P < .001) and higher inflammatory and fibrostenotic features scores in adults than children (3.0 vs 1.0 and 3.0 vs 0, respectively; both P < .001). Total I-SEE score had a bimodal distribution with the inactive to moderate categories and severe category. EDP score correlated with total I-SEE score (r = −0.352, P < .001) and both inflammatory and fibrostenotic features scores (r = −0.665, P < .001; r = −0.446, P < .001, respectively), but not with symptoms and complications scores (r = 0.047, P = .408). Molecular severity increased from inactive to mild and moderate, but not severe, categories. Longitudinal changes of modified I-SEE scores and inflammatory and fibrostenotic features scores reflected histologic and molecular activity. Conclusions: I-SEE score is associated with select clinical features across severity categories and with EoE molecular features for nonsevere categories, warranting further validation.
AB - Background: The Index of Severity for Eosinophilic Esophagitis (I-SEE) is a new expert-defined clinical tool that classifies disease severity of eosinophilic esophagitis (EoE). Objective: We aimed to determine whether I-SEE is associated with patient characteristics, molecular features of EoE, or both. Methods: We analyzed a prospective cohort of patients with EoE from the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). Associations between I-SEE and clinical and molecular features (assessed by an EoE diagnostic panel [EDP]) were assessed. Results: In 318 patients with chronic EoE (209 adults, 109 children), median total I-SEE score was 7.0, with a higher symptoms and complications score in children than adults (4.0 vs 1.0; P < .001) and higher inflammatory and fibrostenotic features scores in adults than children (3.0 vs 1.0 and 3.0 vs 0, respectively; both P < .001). Total I-SEE score had a bimodal distribution with the inactive to moderate categories and severe category. EDP score correlated with total I-SEE score (r = −0.352, P < .001) and both inflammatory and fibrostenotic features scores (r = −0.665, P < .001; r = −0.446, P < .001, respectively), but not with symptoms and complications scores (r = 0.047, P = .408). Molecular severity increased from inactive to mild and moderate, but not severe, categories. Longitudinal changes of modified I-SEE scores and inflammatory and fibrostenotic features scores reflected histologic and molecular activity. Conclusions: I-SEE score is associated with select clinical features across severity categories and with EoE molecular features for nonsevere categories, warranting further validation.
KW - Eosinophilic esophagitis
KW - complications
KW - diagnostic panel
KW - eosinophil
KW - outcome
UR - http://www.scopus.com/inward/record.url?scp=85195473255&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2024.04.025
DO - 10.1016/j.jaci.2024.04.025
M3 - Article
C2 - 38750825
AN - SCOPUS:85195473255
SN - 0091-6749
VL - 154
SP - 375-386.e4
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 2
ER -